New RSV vaccine candidate enters human safety testing
NCT ID NCT07106918
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This early-stage study is testing a new vaccine called SIBP-A16 to see if it is safe and how the body processes it. The trial involves 140 healthy adults aged 18 to 45. Researchers will monitor for side effects and measure how the vaccine behaves in the body. This is a first step to see if the vaccine can be developed further to protect against RSV, a common respiratory virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Jinyintan Hospital
RECRUITINGWuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.